On the value of doing nothing: anger and cardiovascular disease in clinical practice

Julie K Schulman1, Shannon Stromberg

  • 1University of Colorado Health Sciences Center, Denver, USA. jksmd@mac.com

Cardiology in Review
|April 18, 2007
PubMed

Insights

Current measurements of Type A behavior, anger, and hostility lack clinical evidence linking them to cardiovascular disease (CVD). Existing data do not support a meaningful relationship between these psychosocial traits and CVD development.

Area of Science:

  • Psychosocial factors and cardiovascular health

Background:

  • Type A behavior, anger, and hostility are considered potential risk factors for cardiovascular disease (CVD).
  • Previous research on these psychosocial traits and CVD has yielded inconsistent results.
  • Variability in measurement methods and outcome endpoints complicates interpretation of existing studies.

Purpose of the Study:

  • To systematically review existing quantitative and qualitative studies on the relationship between Type A behavior, anger, hostility, and CVD.
  • To assess the clinical significance of current measurements of these psychosocial traits in relation to CVD development.

Main Methods:

  • Conducted a comprehensive review of quantitative (meta-analytic) and qualitative systematic reviews.
  • Utilized Database of Abstracts of Reviews of Effects (DARE) criteria for study selection and evaluation.

Main Results:

  • The reviewed studies exhibit significant heterogeneity in methodologies and outcome measures.
  • Analysis of existing data did not reveal a consistent or clinically meaningful association.
  • Disparate results were observed across the evaluated studies.

Conclusions:

  • The current evidence does not support a significant clinical relationship between commonly measured psychosocial traits (Type A behavior, anger, hostility) and the development of cardiovascular disease.
  • Further research with standardized methodologies may be warranted, but current data are insufficient.

Related Concept Videos

Exercise and Cardiovascular Response01:20

Exercise and Cardiovascular Response

Exercise significantly impacts cardiovascular response, which is crucial for understanding patient health and designing effective treatment plans.
Light to moderate physical activity initiates a series of interconnected responses in the body. The heart rate modestly increases in anticipation of the workout, followed by widespread vasodilation as oxygen consumption by skeletal muscles increases. This results in decreased peripheral resistance, increased capillary blood flow, and accelerated...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Angina III: Clinical Manifestations and Assessment01:29

Angina III: Clinical Manifestations and Assessment

Angina manifests as chest pain, tightness, or squeezing discomfort typically located behind the breastbone. It can radiate to the neck, jaw, shoulders, and inner aspects of the upper arms, most commonly the left arm. Patients may experience shortness of breath, fatigue, profuse sweating, dizziness, indigestion, heartburn, palpitations, anxiety, and vomiting as accompanying symptoms. This pain often lasts a few minutes and is triggered by physical exertion, emotional stress, heavy meals, or cold...